This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bryant, G. Articles by Liotta, L. A. Search for Related Content PubMed PubMed Citation Articles by Bryant, G. Articles by Liotta, L. A.

Butyrate Induced Reduction of Tumor Cell Laminin Receptors

Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205 [G. B., C. N. R., L. A. L.], and Department of Microbiology, Boston University School of Medicine, Boston, Massachusetts 02215 [C. H.]

Laminin, a glycoprotein of basement membranes, binds to the surface of cultured human pancreatic carcinoma cells (PANC-1). The binding is saturable, with a high proportion of specific binding, as determined by competition of labeled ligand with 80-fold excess unlabeled ligand. Pretreatment of the carcinoma cells with butyrate markedly reduces the amount of specific laminin binding. The butyrate effect on laminin binding is dose dependent and is observed at a concentration of butyrate which does not significantly reduce cellular protein synthesis or increase laminin production. Scatchard analysis indicates that butyrate reduces the total number of laminin binding sites without affecting the binding coefficient (K_d = 2 nm). The laminin receptor protein isolated from the PANC-1 cell extract has a molecular weight of approximately 70,000. After butyrate treatment the total amount of extractable laminin receptor protein is significantly reduced. Thus butyrate reduces laminin binding to PANC-1 carcinoma cells by a mechanism which involves decreased expression of laminin receptor proteins in the plasma membrane.

¹ To whom requests for reprints should be addressed.

Received 2/12/85. Revised 6/28/85. Revised 10/15/85. Accepted 10/29/85.